Navigation Links
Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
Date:10/7/2008

ater this year. In addition, RDEA119 is being evaluated in a Phase 1 trial in patients with advanced cancer, and will be also be evaluated in a Phase 1/2 clinical trial in the fourth quarter of 2008 in combination with Nexavar(R) (sorafenib) in advanced cancer patients. The Company also plans to initiate a Phase 1 trial of RDEA436, its second-generation MEK inhibitor, in healthy volunteers, in the fourth quarter of this year.

About RDEA119 and RDEA436

RDEA119 and RDEA436, non-ATP competitive, highly-selective MEK inhibitors for the treatment of cancer and inflammatory diseases, are two of the compounds from Ardea's MEK inhibitor research and development program. RDEA119 has shown potential as a potent and selective inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. Preclinical data show that RDEA436 is a potent in-vitro and in-vivo inhibitor of MEK, has favorable pharmacokinetic properties with low CNS penetration and a long half-life in a human micro-dose study indicating the potential for once daily dosing in humans.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV,
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
2. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
3. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
4. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
5. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
6. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
7. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
11. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Cardiologists at Henry Ford ... stroke in patients with an irregular heartbeat. With ... Henry Ford is able to add another option ... fibrillation, which affects the heart,s ability to pump. ... and first-ever commercial Watchman implant at a non-clinical trial ...
(Date:4/21/2015)... -- According to a new market ... Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), ... Contamination, Adventitious Agents) - Global Forecast to 2019", ... Market was valued at $1,758.69 Million in 2014. ... CAGR of 12.23% to reach $3,130.85 Million in ...
(Date:4/21/2015)... -- Seattle Children,s announced today that 20 of 22 ... genetically reprogrammed T cells to treat relapsed acute lymphoblastic ... sensitive tests designed to detect minute amounts of cancer ... included children with very high tumor burdens as well ... "These results are extremely encouraging," said ...
Breaking Medicine Technology:Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 2Biologics Safety Testing Market Worth $3,130.85 Million by 2019 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 4Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 2Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 3
(Date:4/21/2015)... 2015 Carinsurancehints.com has released a new ... their impact on auto insurance prices . ... insurance prices. Clients should review their insurance options before ... bought under several forms. Some of the popular policies ... can compare online rates and find the best prices ...
(Date:4/21/2015)... On April 8th, 2015, Choices Recovery sponsored ... world famous Avalon Hollywood. Organized by Debbie Durkin, Los ... and film, the EcoLuxe Lounge is a premier red ... and festivals throughout the year. A gathering of some ... conscious products and services, this daylong event is attended ...
(Date:4/21/2015)... Edward Avalos, USDA Under Secretary for Marketing and ... the California Department of Food and Agriculture, have been ... Conference: The Future of Local Food, conference organizers announced ... known experts intensifies an already strong line-up of sustainable ... to speak at the June 11-13 event. ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 The ... Citrate Industry is a professional and in-depth study ... Sodium Citrate Market with a focus on ... in the sodium citrate market research are Cargill, ... Natural Biological, Cofco Biochemical, Capchem, Lianyungang Mupro Fi, ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Respected ... PACS® strategy , Visage Imaging Inc. (“Visage”), ... PME), has signed a seven-year contract with University ... in Northern Florida. The deal furthers the penetration ... hospital space, a key area of the North American ...
Breaking Medicine News(10 mins):Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4
... ... be a profitable 2010, the new Wella SP range is set to raise the ... ... hair company in the world, Wella is at the forefront of hairdressing innovation. The introduction ...
... ... struggle to find the balance between investing in the necessary internal resources to implement ... for a dozen online tactics, and identifies where companies are using each tactic in ... ...
... ... of the most common negative patterns in a relationship. Angry individuals may be aware of ... Path.com. , ... (PRWEB) February 1, 2010 -- Personal Power Path announces the launch of an anger management ...
... , Feb. 1 /PRNewswire / -- Ervin Cohen ... announced today that David Bricker , Of Counsel to ... clients last Friday, January 29, 2010 , in a medical malpractice ... Hopp of the Riverside Superior Court and a jury panel of 12. ...
... , BIRMINGHAM, Ala. , Feb. 1 ... Jon P. Stonehouse , President and Chief Executive Officer of BioCryst, plans ... forodesine and BCX4208 at the 12 th Annual BIO CEO ... at 10:30 a.m. Eastern Time . , Links to a ...
... contrast agent gadolinium during magnetic resonance imaging (MRI) for ... metastases, according to a new study published online February ... Institute . Gadolinium-enhanced MRI is primarily used to visualize ... and evaluate lymph node metastases. In light of this ...
Cached Medicine News:Health News:ckwrites.com Releases Report On Creating Online Marketing Tactics 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 3Health News:BioCryst To Present At 12th Annual BIO CEO & Investor Conference 2Health News:News brief: Contrast agent with MRI improves detection of lymph nodes metastases 2
The GelAir™ dryer is a component of the GelAir drying system. Supplied as a 230 V, 50 Hz gel drying oven....
... The PRO6000 power supply is ... power supply product offering. It ... and genomic electrophoresis. This product ... proteomic applications such as microAmp ...
... Operating as a constant voltage power supply, the ... knob and hilo range switch control the output, ... to 250 volts. One, two-position switch toggles the ... output current. The 105 is equipped with an ...
... The 250-90 low voltage electrophoresis power supply ... 500 milliamps and 125 watts. This product operates ... continuously variable output. The 250-90 automatically crosses over ... when a preset limit is reached. ...
Medicine Products: